Zura Bio Ltd Dossier - Source-backed chat

Zura Bio Ltd

ZURANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.32

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.16Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $398.6M

Enterprise Value $193.5M

Shares Outstanding 95.8M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Zura Bio is a clinical-stage biotechnology company advancing a promising immunology pipeline, led by tibulizumab (ZB-106), a first-in-class bispecific antibody targeting both IL-17A and BAFF pathways. While the company's balance sheet has been significantly strengthened by a $144 million equity raise in February 2026, extending its cash runway through 2028, the near-term investment thesis is highly binary. The primary value driver is the upcoming Phase 2 TibuSHIELD readout in hidradenitis suppurativa (HS) expected in Q4 2026. Although IL-17A is a validated target in HS, the incremental clinical benefit of BAFF inhibition remains unproven in this indication. Given the highly competitive and crowded landscape of HS therapies, a Hold rating is recommended until clinical data validates the dual-pathway mechanism and demonstrates meaningful therapeutic differentiation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$15.67

High · most bullish analyst$26.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0015%

The TibuSHIELD trial fails to meet its primary efficacy endpoints or fails to show any incremental benefit from adding BAFF inhibition to IL-17A neutralization in Q4 2026. The failure severely damages the dual-pathway thesis for tibulizumab, causing the stock to decline sharply. The company is forced to pivot to its earlier-stage assets (ZB-168 and ZB-880) or seek strategic alternatives, with its cash balance acting as a partial valuation floor.

Base CaseCentral scenario

$11.0050%

Tibulizumab demonstrates positive, clinically meaningful efficacy in the TibuSHIELD trial in Q4 2026, confirming the safety and therapeutic potential of the dual-pathway mechanism. However, the incremental benefit over existing IL-17 inhibitors is moderate, leaving questions about its ultimate commercial positioning in a crowded market. The stock experiences moderate appreciation, supported by its robust cash runway through 2028, as investors look forward to the TibuSURE (SSc) readout in H1 2027.

Bull CaseUpside scenario

$15.0035%

The Phase 2 TibuSHIELD trial in HS delivers outstanding topline results in Q4 2026, demonstrating that dual IL-17A and BAFF inhibition provides superior efficacy and durable disease control compared to existing single-pathway biologics. This clinical validation triggers rapid upward revisions of the drug's market potential in the $8 billion HS market and the $4 billion SSc market, attracting major pharmaceutical partnerships and driving significant share price appreciation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class bispecific antibody (tibulizumab) targeting dual validated pathways (IL-17A and BAFF) involved in complex autoimmune pathogenesis.
Strong financial position with $225.6 million in cash as of March 31, 2026, providing an operational runway through at least the end of 2028 and removing near-term financing risk.
Experienced leadership team, led by newly appointed CEO Dr. Sandeep Kulkarni, with a proven track record of successful biotech development and value creation.

Key Investment Risks

High clinical development risk, with the company's valuation heavily tied to the binary outcome of the Phase 2 TibuSHIELD trial in Q4 2026.
Intense competition in the hidradenitis suppurativa (HS) market from established single-pathway biologics and other advanced pipeline candidates.
Unproven therapeutic synergy of adding BAFF inhibition to IL-17A neutralization in the treatment of HS.

Thesis Invalidation Triggers

Failure of the Phase 2 TibuSHIELD trial to meet its primary efficacy or safety endpoints in Q4 2026.
Significant delays in clinical trial enrollment or regulatory timelines for the TibuSHIELD or TibuSURE studies.
Unexpected safety signals or adverse events emerging from ongoing clinical trials of tibulizumab.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.